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Abstract 
Introduction 
Ipsilateral breast recurrence or second primary breast cancer can develop in patients who have 
undergone breast conserving surgery (BCS) and axillary surgery. The purpose of this study 
was to examine the feasibility of a reoperative sentinel lymph node biopsy (SLNB) as a 
repeated axillary staging procedure. 
 
Patients and Methods 
From August 2014 through January 2017 patients with locally recurrent breast cancer or with 
BRCA mutation requiring risk reduction mastectomy as a second surgical procedure, 
underwent repeat SLNB in three Hungarian Breast Units with a radiocolloid (and blue dye) 
technique.  
  
Results  
Hundred and sixty repeat SLNBs were analysed, 80 after previous SLNB and 80 after 
previous total or partial axillary lymph node dissection (ALND). SLN identification was 
successful in 106 patients (66%); 62/80 (77.5%) and 44/80 (55%) in the SLNB and ALND 
groups, respectively. (p<0.003). Extra-axillary lymph drainage was more frequent in the 
ALND group (19/44, 43,2% versus 7/62, 11,3%;p<0.001). Lymphatic drainage to the 
contralateral axilla was observed in 14 patients (11 in the ALND group, p=0.025), isolated 
parasternal drainage was detected in 4 patients (p=0.31).  Only 9/106 patients with successful 
repeat SLNB (8,8%, all with 1 SLN removed) had SLN metastases   
 
Repeat SLNB is feasible and accurate for 66% of in patients with ipsilateral breast tumor 
recurrence or new ipsilateral primary tumor after previous BCS and axillary staging, 
especially after a previous SLNB. Repeat SLNB should replace routine ALND as the standard 
axillary restaging procedure in recurrent disease with a clinically negative axilla. Preoperative 
lymphoscintigraphy is important to explore extra-axillary lymphatic drainage in this restaging 
setting. 
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Introduction 
For all breast cancers, the local recurrence rate following breast conserving surgery (BCS) is 
reported to be about 5-10% at ten years follow-up (1-3). There is no definite consensus 
regarding the best strategy for managing the regional lymph nodes in patients with local 
recurrences and clinically negative axilla (4-5, 23). Similarly, there has been no prospective, 
randomized trial that showed a survival or regional control benefit of completion axillary lymph 
node dissection (ALND) for patients with local recurrence after BCS with sentinel lymph node 
biopsy (SLNB) (6). Previous breast cancer treatment with surgery and/or radiotherapy of the 
breast and axilla could lead to disrupted lymph drainage by scar tissue and fibrosis (7). A 
previously operated axilla was considered to be a relative contraindication for performing an 
SLNB, but there is evidence supporting the use of SLNB in the reoperative setting (8-10). 
Lymphatic drainage after previous breast surgery would be altered and it remains questionable 
whether SLNB at the time of surgery for locally recurrent breast cancer (repeat SLNB, re-
SLNB) is technically feasible, and whether ALND can safely be omitted if repeat SLNB yields 
lymph nodes free of metastasis (11-14). The aim of this study is to evaluate technical feasibility 
of performing reoperative SLNB in patients with ipsilateral recurrent breast cancer. 
 
Patients and Methods 
From, patients with locally recurrent breast cancer or  BRCA gene germline mutation carriers 
in need of risk reduction mastectomy as a second surgical procedure who underwent re-SLNB 
in three Hungarian Breast Units from August 2014 through January 2017 formed the study 
population.  
SLNB procedure and axillary management 
Lymphatic mapping was performed using technetium-99m-labeled tin colloid (particle 
diameter: 0.2 - 0.4 mm) or albumin (particle size up to 0.1 m). The colloid was injected 
periareolary or peritumorally on the day before the operation. Lymphoscintigraphy was 
performed on the next morning. In case of contralateral axillary drainage, the removal of the 
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labelled SLNs was attempted, but parasternal (internal mammary) SLNs were not removed. If 
the lymphoscinfigraphy showed only internal mammary chain drainage, the re-SLNB was 
unsuccessful, but was recorded as aberrant.  Sentinel lymph nodes (SLNs) were identified by a 
handheld gamma probe (Europrobe, … France ). The blue dye technique was used either 
regularly or in patients in whom lymphoscintigraphy failed to highlight a lymph node: 2 ml 
Patent V blue dye was injected periareolarly or peritumorally. If no axillary SLN could be 
identified with the methods above, an ALND (after SLNB) or axillary revision (after ALND) 
was performed depending on the type of axillary surgery performed before. A completion 
ALND to evaluate the false negative rate of re-SLNB was not routinely performed in patients 
with successfully identified SLNs. SLNs were fixed in 10%-formalin solution and embedded 
in paraffin. SLNs greater than 4 mm were cut into approximately 2 mm thick slices and step 
sectiond at 200 or 250 μm. The least exhaustive histology protocol investigated 3 step sections 
from each slice with hematoxylin and eosin (H&E) staining, whereas the most exhaustive one 
looked at 5 step sections, 4 consecutive ones with H&E, and the fifth with cytokeratin 
immunohistochemistry, if the former sections were negative.  
 
Statistical analysis 
Patient data were captured on standardized registration forms. Lymphoscintigraphies showing 
drainage outside the ipsilateral axilla were recorded as aberrant drainage. Descriptive statistics 
were used in this study. Statistical differences between groups, re-SLNB identification rates 
and aberrant drainage were determined using the Chi square test. A p value under 0.05 was 
considered statistically significant. Data were analysed using IBM SPSS Statistics version 19 
or 22 (SPSS Inc., Chicago, IL, USA). 
 
Results 
A total of 160 patients were collected from the 3 centres. Of these, 134 were treated at the 
National Institute of Oncology (NIO) in Budapest, 15 at the Bács-Kiskun County Teaching 
Hospital in Kecskemét and 11 at the University of Szeged. Fifteen patients with BRCA gene 
mutations without any recognizable recurrent tumour – all from the NIO - underwent risk 
reduction mastectomy as a second surgery. 
The median age at diagnosis of the recurrence or at the second surgical procedure in case of 
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risk reduction oncoplastic mastectomy was 62 years (range 31-87 years). All patients underwent 
BCS for their primary tumours.  Patients were divided into two groups on the basis of previous 
axillary surgery: 80/160 had SLNB and 80/160 patients had complete or partial (incomplete, 
with less than 10 axillary lymph nodes removed) ALND before re-SLNB. The mean number of 
lymph nodes removed at the time of primary axillary surgery with SLNB and ALND was 1.7 
(range 1-3) and 13.2 (range 6-21), respectively. Breast irradiation after the primary tumour was 
performed in 152 patients (95%) (TABLE1).  At the time of second surgery and re-SLNB, 
oncoplastic mastectomy (n=28), radical mastectomy (n=105) and repeat BCS (n=27) were 
performed.  
Identification rate and aberrant lymph drainage 
Reoperative sentinel node identification was successful in 106 of the 160 patients (66%). The 
identification rate was 77.5% (62/80) in the SLNB group and 55% (44/80) in the ALND group 
(p=0.003). The average number of SLNs removed was 1.65 (range 1-6) overall, 1.63 (range 1-
5) after previous SLNB and 1.68 (range 1-6) after ALND, respectively. Twenty-six patients 
(26/106, 24.5%) showed aberrant lymph drainage pathways, which was more frequent in the 
ALND group (19/44, 43.2%) than in the SLNB group (7/62, 11.3%) (p<0.001) (TABLE2). 
Lymphatic drainage to the contralateral axilla was observed in 14 patients (3 vs. 11, in the 
SLNB and the ALND group, respectively (p=0.025), isolated parasternal drainage was detected 
in 4 patients (p=0.31). Sites and numbers of patients with aberrant drainage at second 
lymphoscintigraphy are shown in TABLE3. There was no patient in whom an SLN could be 
identified with the blue dye technique, after a failure of lymphoscintigraphy to highlight a 
lymph node.  
Of the 106 patients with successful re-SLNB, 93 (91.2%) were pathologically node-
negative (rpN0).  In 9 (8.8%) patients, re-SLNBs yielded a metastatic lymph node; all these 
patients had only 1 SLN removed.  In 6 of the 9 involved SLNs only micrometastases (rpNmi) 
were detected, and no completion ALND was done. In the remaining three patients (rpN1), who 
all received whole breast irradiation at the time of their first operation, completion ALND was 
performed as a second procedure. Of the metastases, seven were located in the ipsilateral axilla 
and two in the contralateral axilla (TABLE4). 
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Discussion 
Re-SLNB after previous SLNB, in patients with recurrent breast cancer, second primary 
breast cancer or prophylactic mastectomy, was successful in 77.5% of our patient population, 
which is comparable with the success rates of other studies (12-16). Reoperative SLNB failed 
to detect new SLNs in 18 of 80 patients (22.5%). We tried to performe reSLNB in patients after 
previous total or partial (incomplete) ALND as well. Sentinel lymph node identification was 
successful in 44 of 80 patients (55%), but aberrant lymphatic drainage was more frequent 
(19/44, 43.2%) in this setting. 
Previous breast or axillary surgery can partially or temporarily interrupt and modify 
lymphatic flow. The main argument against re-SLNB is that the lymphatic channels and 
drainage are considered to be disrupted due to fibrosis after axillary surgery and radiotherapy 
(17-19). Therefore, it is important to use preoperative lymphoscintigraphy to explore whether 
new SLNs can be identified. The reported percentage of “aberrant” lympatic drainage pathways 
outside the ipsilateral axilla in patients with previous BCS and axillary surgery is 2-47% (20-
21).  Ploeg  suggested that the drainage outside the axilla in the treated breast is higher than that 
in the untreated breast (51 vs. 33 %, P = 0.003) (22). Schrenk et al. demonstrated a significant 
correlation between the identification rate and a positive lymphoscintigraphy, therefore, they 
recommend performing lymphoscintigraphy at the time of surgery for ipsilateral breast cancer 
recurrence (13). They also underline the usefulness of indo-cyanine green (ICG) fluorescence 
method for identifying aberrant lymphatic drainage.  
Maaskant-Braat et al, also reported that aberrant drainage was seen more frequently in 
cases after previous ALND than in those with previous SLNB (79.3 vs. 25.0 %, P=0.0001) (10). 
A recent systematic review and meta-analysis  by Maaskant-Braat et al. analysed 692 from 25 
studies patients with locally recurrent breast cancer who underwent re-SLNB. Of these patients, 
301 had undergone previous SLNB, 361 had undergone ALND. The overall identification rate 
was 65.3 % (452 of 692 patients), but the rate was significantly higher for patients who had 
undergone previous SLNB (81.0 %, 243 of 301 patients) than for patients who had undergone 
ALND (52.2 %, 166 of 318 patients). Aberrant drainage pathways were visualized in 43.2 % 
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of these patients, which was more frequent after ALND than after SLNB (69% vs 17% among 
patients with successful lymphatic mapping, and 33% vs 14% among all patients). Although 
completion ALND was not done in all patients with negative SLN, there were no false-
negatives among 63 SLN-negative procedures validated by a planned ALND, and subsequent 
axillary recurrence developed in only one of these latter patients (8). 
The concept of repeat SLNB has emerged in recent years, but still no consensus on 
guidelines exists regarding the optimal management of lymph nodes in patients with ipsilateral 
breast cancer recurrence and the impact of nodal involvement on prognosis is still unclear. It is 
possible, that the positive re-SLNB in recurrent breast cancer does not have the same 
importance in the choice of adjuvant systemic therapy as in the primary breast cancer (24).  The 
CALOR (chemotherapy for isolated locoregional breast cancer) trial found, that adjuvant 
chemotherapy should be recommended for patients with completely resected isolated 
locoregional recurrences of breast cancer, especially if the recurrence is oestrogen receptor 
negative (25). Although systemic therapy given to locoregional recurrence improved survival 
in this trial, removal of the locoregional relapse was also mandated in this trial, and re-SLNB 
may also help in tailoring local therapy, when only SLNB had been done previously. Ugras et 
al. also reported that the re-SLNB is worthwhile in all patients with invasive local recurrences 
and clinically negative nodes, but the use of systemic therapy and subsequent radiation is 
increasingly defined by the tumor subtype rather than by nodal involvement (26).  
 
 
Conclusions  
 
Our findings are consistent with prior studies which imply that re-SLNB is feasible, and 
may provide a conservative alternative to ALND for breast cancer patients (whether with a new 
primary or a recurring cancer) who have had a previous axillary operation, SLNB or sometimes 
(partial) ALND. We propose that re-SLNB is a further step in deescalating radical axillary 
surgery in the circumstances described above, but its value in treatment tailoring, its morbidity 
and its comparability to no further surgery has to be established. The current axillary 
managment in recurrent breast cancer is an additional axillary evaluation with re-SLNB for all 
patients who are clinically node negative (including axillary ultrasound evaluation in the 
assessment) following BCT and SLNB. We recommend to use preoperative 
lymphoscintigraphy, paying attention to the contralateral axilla and the internal mammary 
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nodes. As the finding of locoregional recurrence or new primary breast cancer generally implies 
adjuvant systemic therapy, the results of nodal involvement are rarely expected to change 
recommendations on adjuvant systemic therapy; however they may change indications of 
radiotherapy (for non irradiated regions). In such cases contralateral and internal mammary 
nodal excision may be indicated.   
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